Aurinia Pharmaceuticals Inc. is a biopharmaceutical company specializing in the development and commercialization of therapies for autoimmune diseases with significant unmet medical needs. The company’s primary focus lies in treating lupus nephritis, a severe complication of systemic lupus erythematosus, through its flagship product, LUPKYNIS. Aurinia also advances a pipeline of investigational therapies, including aritinercept, a dual inhibitor targeting key pathways in autoimmune disease progression. Operating at the intersection of innovation and patient care, the company aims to address gaps in treatment options for complex autoimmune conditions.

The company generates revenue primarily through the sale of LUPKYNIS, its FDA-approved oral therapy for active lupus nephritis in adults. Sales are conducted directly in the United States via specialty pharmacies and a specialty distributor, while international markets, including Europe and Japan, are served through a collaboration with Otsuka Pharmaceutical Co., Ltd. Aurinia supplies LUPKYNIS inventory to Otsuka at cost plus a margin, earning additional milestone payments and royalties ranging from 10% to 20% on net sales in the Otsuka Territories. In 2025, net product sales reached $271.3 million, reflecting a 25% increase over the prior year.

The company operates through the following segments.

• Commercialized Therapies: This segment centers on the marketing and distribution of LUPKYNIS, the first and only FDA-approved oral therapy for lupus nephritis. Aurinia manages direct sales in the U. S. through its commercial organization, while Otsuka handles commercialization in Japan, Europe, the U. K., and Switzerland. The segment also includes revenue from supply agreements, milestone payments, and royalties tied to LUPKYNIS sales in international markets.

• Research and Development: This segment focuses on the advancement of aritinercept, a dual inhibitor of BAFF and APRIL, designed to treat a broader spectrum of autoimmune diseases. Aritinercept is currently in early-stage clinical development, with plans to initiate studies in additional autoimmune indications by 2026. The segment encompasses preclinical and clinical trial activities, regulatory strategy, and intellectual property protection for pipeline assets.

Aurinia Pharmaceuticals Inc. holds a distinctive position in the autoimmune disease treatment landscape, particularly in lupus nephritis, where LUPKYNIS remains the only FDA-approved oral therapy. The company competes with injectable alternatives such as GSK’s BENLYSTA and Genentech’s GAZYVA, as well as off-label use of older immunosuppressants like tacrolimus. Aurinia’s competitive advantages include LUPKYNIS’s oral administration, which enhances patient convenience, and its robust clinical data demonstrating rapid proteinuria reduction and improved renal outcomes. The drug’s dual mechanism of action, targeting calcineurin inhibition and immune modulation, further differentiates it from existing treatments. In the broader autoimmune space, aritinercept faces competition from other dual BAFF/APRIL inhibitors, but its engineered high-affinity binding and favorable immunoglobulin reduction profile may provide a therapeutic edge.

The company’s customer base primarily consists of patients with active lupus nephritis, a severe autoimmune condition affecting the kidneys. In the U. S., LUPKYNIS is distributed through specialty pharmacies and a specialty distributor, serving healthcare providers and institutions that treat lupus patients. Internationally, Aurinia’s collaboration partner, Otsuka Pharmaceutical Co., Ltd., markets the drug to healthcare systems and providers in Europe, Japan, the U. K., and Switzerland. The end users are individuals suffering from lupus nephritis, a subset of the broader systemic lupus erythematosus population, which is estimated to include over 200,000 people in the U. S. alone.